The American Society of Hematology sent two updates today. One on lymphoma and lymphoid neoplasms, and one from the 2021 ASCO Annual Meeting:
A recent study suggests the systemic therapies that survivors of pediatric cancers receive may impact their long-term cognitive outcomes, with negative effects on education, employment, and income
ASH Clinical News is following the 2021 ASCO Annual Meeting to report on the latest advances in hematologic malignancies. Here’s a look at some of the highlights:
Investigating the Combination of Ivosidenib Plus Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies
Treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high rates of complete responses in patients with acute myeloid leukemia.
Can Participation in Cancer Clinical Trials Save Money?
Patients with cancer who were treated as part of a clinical trial had lower costs of care than similar patients who were receiving routine care, according to an analysis from a large community-based oncology practice.
Functional, Nutritional, and Social Status Predict Survival Outcomes in Older Patients with CLL
These geriatric domains were associated with overall survival and progression-free survival in older adults with chronic lymphocytic leukemia.